Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

NCT03556956 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Masitinib

Sponsor

AB Science